Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly Stock Pops on Drug Efficacy for Sleep Apnea
10:40am, Wednesday, 17'th Apr 2024
Eli Lilly And Co (NYSE:LLY) stock was last seen up 2.8% at $767.65, after the pharmaceutical giant said data from two late-stage trials showed its weight loss drug Mounjaro helped reduce irregular
Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says
09:38am, Wednesday, 17'th Apr 2024
The U.S. Food and Drug Administration website showed that most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarte
Eli Lilly's weightloss drug helps reduce sleep apnoea
08:55am, Wednesday, 17'th Apr 2024
The Eli Lilly and Co (NYSE:LLY) weightloss drug Tirzepatide, known as Zepbound and Mounjaro, has also been shown in two trials to help improve the symptoms of sleep apnea. Tirzepatide "meaningfully
Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients
06:43am, Wednesday, 17'th Apr 2024
Eli Lilly's weight-loss drug succeeded in two late-stage trials testing it in patients with obstructive sleep apnea, the company said on Wednesday.
Eli Lilly reports positive data in Phase 3 trial of weight-loss drug as treatment for sleep apnea
06:30am, Wednesday, 17'th Apr 2024
Eli Lilly & Co. LLY, -0.54% said Wednesday that two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced sleep a
Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trials
06:16am, Wednesday, 17'th Apr 2024
The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
07:09pm, Tuesday, 16'th Apr 2024
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
06:51pm, Tuesday, 16'th Apr 2024
In the closing of the recent trading day, Eli Lilly (LLY) stood at $749.26, denoting a -0.2% change from the preceding trading day.
Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drug
09:22am, Monday, 15'th Apr 2024
Atossa Therapeutics Inc (NASDAQ:ATOS) and its research partner Quantum Leap Healthcare Collaborative announced the initiation of a new study evaluating Atossa's lead drug candidate (Z)-endoxifen in co
Novo Nordisk and Eli Lilly weight loss drugs may not be a silver bullet, but they have huge potential, says leading US bank
08:46am, Monday, 15'th Apr 2024
A staggering $1 trillion could be the annual cost to the US healthcare system if 40% of Americans with obesity begin treatment with GLP-1 drugs at current prices, according to Dr Jonathan Gruber, th
3 Magnificent Stocks That Could Double or More by 2030
08:47am, Saturday, 13'th Apr 2024
CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
10:05am, Friday, 12'th Apr 2024
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
09:27am, Friday, 12'th Apr 2024
The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
09:11am, Friday, 12'th Apr 2024
Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analysts s
Popular weight-loss drug doesn't increase suicide risk, EU regulator says
07:11am, Friday, 12'th Apr 2024
A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.
